Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05030987
Other study ID # UNLOAD-HFpEF
Secondary ID CIV-20-10-034846
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2021
Est. completion date March 31, 2026

Study information

Verified date April 2023
Source University of Leipzig
Contact Philipp Lurz, Prof. Dr.
Phone 49 341
Email philipp.lurz@medizin.uni-leipzig.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart failure with preserved ejection fraction has a high mortality, which is contrasted by a total absence of therapy options besides symptomatic diuretic treatment. This study aims to explore the potential of renal denervation as a treatment option for heart failure with preserved ejection fraction.


Description:

Heart failure is one of the most important diseases worldwide, with a 5-year mortality of up to 75% in symptomatic patients. While substantial progress has been made in the treatment of patients with reduced left ventricular ejection fraction (HFrEF), mortality for patients with heart failure and preserved ejection fraction (HFpEF) remains unchanged, despite a comparable prevalence and mortality of the disease as for heart failure with reduced ejection fraction. HFpEF is a heterogeneous condition and has been a diagnostic and therapeutic challenge for clinicians and researchers over the past decades. While some rare cases of HFpEF can be attributed to specific diseases like amyloidosis, in most other patients common characteristics are increased ventricular filling pressures and ventricular and arterial stiffening as frequently caused by ageing, diabetes and arterial hypertension. Furthermore, increased sympathetic activity has been described as one pathogenic contributor to chronic heart failure and is associated with poor clinical prognosis. It also leads to a more pulsatile BP profile which can cause a mismatch in arterio-ventricular coupling. The modulating effects on the sympathetic nervous system induced by renal denervation (RDN) should be beneficial in HFpEF, as they improve resting and exercise hemodynamics due to an improved ventriculoarterial coupling by reduced aortic stiffness and lower systemic blood pressure. In addition, RDN leads to optimized stroke volume and stroke work and might affect cardiac preload by improving blood distribution into the splanchnic compartment. This study aims to explore the potential of RDN as a therapy for HFpEF in a single center pilot trial using a randomized, sham-controlled double-blind design.


Recruitment information / eligibility

Status Recruiting
Enrollment 68
Est. completion date March 31, 2026
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. confirmed arterial hypertension (1-5 antihypertensive drugs without any dosage change in the preceding 4 weeks) and average systolic BP between >125 and =170 mmHg and diastolic BP =110 mmHg in 24h ambulatory blood pressure measurement (ABPM) 2. HFpEF (defined by clinical signs and/or symptoms of heart failure, objective structural cardiac abnormalities according to the ESC criteria [1], elevated NT-proBNP =125 pg/mL and left-ventricular ejection fraction =55%) 3. NYHA-Class II or III 4. Confirmation of an elevated cardiac filling pressures (either LVEDP >= 16 mmHg or PCWP >= 15 mmHg at rest or >=25 mmHg during exercise) by catheterization 5. Age 18-80 years 6. Written informed consent Exclusion Criteria: 1. =1 main renal artery diameter <3.0 mm 2. main renal artery length < 20 mm 3. a single functioning kidney 4. presence of abnormal kidney tumors 5. renal artery aneurysm 6. pre-existing renal stent or history of renal artery angioplasty 7. fibromuscular disease of the renal arteries 8. presence of renal artery stenosis of any origin =50% 9. iliac/femoral artery stenosis precluding femoral access for RDN 10. fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects of the trial device on contraception). 11. participation in other interventional trials 12. patients under legal supervision or guardianship 13. suspected lack of compliance 14. pregnant women 15. Presence of intracardiac pacemakers or implantable cardioverter/defibrillators

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Renal Denervation
Renal denervation in patients with HFpEF and uncontrolled hypertension
Sham
Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.

Locations

Country Name City State
Germany Herzzentrum Leipzig, Universitätsklinik für Kardiologie Leipzig

Sponsors (2)

Lead Sponsor Collaborator
University of Leipzig ReCor Medical, Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary exercise PCPW at 20 W workload To assess the hemodynamic effects of RDN in patients with HFpEF in comparison to sham-treatment 6 months after randomization
Secondary number of combination of death, increase in diuretic therapy, hospitalization for heart failure, worsening NYHA-class, change in pulmonary pressure parameters number of combined endpoint in RDN and SHAM patients 6, 12 and 24 months after RDN
Secondary Change in mean PA pressure, ePAD and PA pressure variability from pulmonary pressure sensor measurements difference between RDN and sham 6 months after randomization
Secondary Change in mean PA pressure, ePAD and PA pressure variability from pulmonary pressure sensor measurements Change in mean PA pressure, ePAD and PA pressure variability from pulmonary pressure sensor measurements, compared to baseline values 6, 12 and 24 months after RDN
Secondary Change in Systolic/Diastolic 24h blood pressure by ABPM and blood pressure variability difference between RDN and sham 6 months after randomization
Secondary Change in Systolic/Diastolic 24h blood pressure by ABPM and blood pressure variability Change in Systolic/Diastolic 24h blood pressure by ABPM and blood pressure variability, compared to baseline values 6, 12 and 24 months after RDN
Secondary Difference in ventriculo-arterial coupling Difference in ventriculo-arterial coupling (by end-systolic elastance and arterial elastance) as acquired by invasive measurement 6 months after randomization
Secondary Change in CMR-based hemodynamics Change in CMR-based hemodynamics (difference between RDN and sham) as compared to baseline values 6 months after randomization
Secondary Change in ventriculo-arterial coupling Change in ventriculo-arterial coupling (cMRI and echocardiogram) (difference between RDN and sham) as compared to baseline values 6 months after randomization
Secondary Difference in resting and exercise PCWP (at 20, 40, 60, 80 W, and maximum workload) Difference in resting and exercise PCWP (at 20, 40, 60, 80 W, and maximum workload) (difference between RDN and sham) as compared to baseline values 6 months after randomization
Secondary Difference in peak PCWP Difference in peak PCWP (difference between RDN and sham) as compared to baseline values 6 months after randomization
Secondary Difference in NT-proBNP Difference in NT-proBNP (difference between RDN and sham) as compared to baseline 6 months after randomization
Secondary Difference in NT-proBNP Difference in NT-proBNP as compared to baseline 6, 12 and 24 months after RDN
Secondary number of patients with Hospitalizations for heart failure number of patients with Hospitalizations for heart failure (difference between RDN and sham) 6 months after randomization
Secondary difference in All-cause Mortality All-cause Mortality (difference between RDN and sham) 6 months after randomization
Secondary difference in cardiac mortality cardiac mortality (difference between RDN and sham) 6 months after randomization
Secondary difference in major adverse cardiovascular events major adverse cardiovascular events (composite of cardiac death, myocardial infarction, stroke and hospitalization for heart failure) (difference between RDN and sham) 6 months after randomization
Secondary difference in number of Adverse Events Adverse events (difference between RDN and sham) 6 months after randomization
Secondary difference in Frequency of patients with controlled hypertension Frequency of patients with controlled hypertension (blood pressure within treatment goals in ABPM as recommended by the European Society of Cardiology) (difference between RDN and sham) 6 months after randomization
Secondary difference in Frequency of patients with controlled hypertension Frequency of patients with controlled hypertension (blood pressure within treatment goals in ABPM as recommended by the European Society of Cardiology) as compared to baseline 6, 12 and 24 months after RDN
Secondary Difference in 6-minute walk distance Difference in 6-minute walk distance (difference between RDN and sham) 6 months after randomization
Secondary Difference in 6-minute walk distance Difference in 6-minute walk distance as compared to baseline 6, 12 and 24 months after RDN
Secondary Change in exercise BP and maximum maximum exercise capacity Change in exercise BP between baseline and 6 months and maximum exercise capacity between baseline and 6 months (difference between RDN and sham) 6 months after randomization
Secondary Change in Minnesota living with heart failure questionnaire (difference between RDN and sham) Change in Minnesota living with heart failure questionnaire (difference between RDN and sham) 6 months after randomization
Secondary Change in Minnesota living with heart failure questionnaire Change in Minnesota living with heart failure questionnaire, compared to baseline 6, 12 and 24 months after RDN
See also
  Status Clinical Trial Phase
Recruiting NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Recruiting NCT05582044 - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction N/A
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1